Development of a capillary electrophoresis‐mass spectrometry method for the determination of rivastigmine in human plasma – Optimization of the limits of detection and quantitation
AbstractA capillary zone electrophoresis‐electrospray ionization‐mass spectrometry (CZE‐ESI‐MS) method was developed for the analysis of the acetylcholinesterase inhibitor rivastigmine. Several electrophoretic and ESI‐MS parameters were investigated in order to improve sensitivity. These parameters were categorized in three areas: (i) background electrolyte (BGE) parameters, (ii) sheath liquid parameters, and (iii) spray chamber parameters. The optimized results were obtained by using 40‐mM ammonium acetate at pH 9 as BGE, a sheath liquid of 1% acetic acid in water:MeOH (50:50 v/v) at a flow rate of 10 μL/min, and a drying gas flow rate that was set at 6 L/min and at a temperature of 200°C. These parameters provided limit of detection and limit of quantitation of 2.8 ng/mL ...div id=medwormpbiMedWorm Message:/i/b Please support the a href=http://www.doctorsinchains.org/ target=_blankDoctors In Chains/a campaign for the a href=http://www.doctorsinchains.org/medics/a tortured and sentenced for up to 15 years in a href=http://www.doctorsinchains.org/Bahrain/a. a href=https://twitter.com/#!/search/%23FreeDoctors#FreeDoctors/a/p/div

Novartis Europharm Ltd Withdraws its Applications for an Extension of the Indication for Exelon and Prometax (rivastigmine)
The European Medicines Agency has been formally notified by Novartis Europharm Ltd of its decision to withdraw its applications for an extension of the therapeutic indication for the centrally authorised medicines Exelon and Prometax (rivastigmine),... (Source: Drugs.com - Pharma News)